Drug-induced arrhythmia

Circulation

Volumn 122, Issue 14, 2010, Pages 1426-1435

  Heist, E Kevin ^a   Ruskin, Jeremy N ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

cardiac arrhythmias; drug therapy; long QT syndrome

Indexed keywords

ASTEMIZOLE; AZIMILIDE; CISAPRIDE; COCAINE; DOFETILIDE; DROPERIDOL; ENCAINIDE; FEXOFENADINE; FLECAINIDE; FLUOXETINE; IBUTILIDE; LITHIUM; MEXILETINE; MIBEFRADIL; POTASSIUM CHANNEL HERG; PROPOFOL; QUINIDINE; SODIUM CHANNEL BLOCKING AGENT; SOTALOL; TERFENADINE; TERODILINE; THIORIDAZINE; TRICYCLIC ANTIDEPRESSANT AGENT;

CARDIOVASCULAR RISK; DRUG INDUCED DISEASE; DRUG INDUCED HEART ARRHYTHMIA; ELECTROCARDIOGRAM; GENETIC ASSOCIATION; HEART ARREST; HEART ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HUMAN; LONG QT SYNDROME; NONHUMAN; POLYMORPHIC VENTRICULAR TACHYCARDIA; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; RISK BENEFIT ANALYSIS; SHORT QT SYNDROME; ST SEGMENT ELEVATION; SUDDEN DEATH; SYNCOPE;

ANTIPSYCHOTIC AGENTS; ARRHYTHMIAS, CARDIAC; DRUG INTERACTIONS; HISTAMINE ANTAGONISTS; HUMANS; INJECTIONS, INTRAVENOUS; LONG QT SYNDROME; QUINIDINE; SODIUM CHANNEL BLOCKERS; SUBSTANCE-RELATED DISORDERS; SYNCOPE;

EID: 77958500384     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.109.894725     Document Type: Review

References (87)

1. Roden DM Clinical practice: long-QT syndrome. N Engl J Med. 2008; 358:169-176.
2. Clancy CE, Kass RS. Inherited and acquired vulnerability to ventricular arrhythmias: cardiac Na+ and K+ channels. Physiol Rev. 2005;85: 33-47.
3. Noseworthy PA, Newton-Cheh C. Genetic determinants of sudden cardiac death. Circulation. 2008;118:1854-1863.
4. Bellocq C, van Ginneken AC, Bezzina CR, Alders M, Escande D, Mannens MM, Baró I, Wilde AA. Mutation in the KCNQ1 gene leading to the short QT-interval syndrome. Circulation. 2004;109:2394-2397.
5. Brugada R, Hong K, Dumaine R, Cordeiro J, Gaita F, Borggrefe M, Menendez TM, Brugada J, Pollevick GD, Wolpert C, Burashnikov E, Matsuo K, Wu YS, Guerchicoff A, Bianchi F, Giustetto C, Schimpf R, Brugada P, Antzelevitch C. Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation. 2004;109:30-35.
6. Schimpf R, Borggrefe M, Wolpert C. Clinical and molecular genetics of the short QT syndrome. Curr Opin Cardiol. 2008;23:192-198.
7. Chugh SS, Senashova O, Watts A, Tran PT, Zhou Z, Gong Q, Titus JL, Hayflick SJ. Postmortem molecular screening in unexplained sudden death. J Am Coll Cardiol. 2004;43:1625-1629.
8. Tester DJ, Ackerman MJ. Postmortem long QT syndrome genetic testing for sudden unexplained death in the young. J Am Coll Cardiol. 2007;49: 240-246.
9. Albert CM, Nam EG, Rimm EB, Jin HW, Hajjar RJ, Hunter DJ, MacRae CA, Ellinor PT. Cardiac sodium channel gene variants and sudden cardiac death in women. Circulation. 2008;117:16-23.
10. Ackerman MJ, Splawski I, Makielski JC, Tester DJ, Will ML, Timothy KW, Keating MT, Jones G, Chadha M, Burrow CR, Stephens JC, Xu C, Judson R, Curran ME. Spectrum and prevalence of cardiac sodium channel variants among black, white, Asian, and Hispanic individuals: implications for arrhythmogenic susceptibility and Brugada/long QT syndrome genetic testing. Heart Rhythm. 2004;1:600-607.
11. Newton-Cheh C, Larson MG, Corey DC, BenJ Amin EJ, Herbert AG, Levy D, D'Agostino RB, O'Donnell CJ. QT interval is a heritable quantitative trait with evidence of linkage to chromosome 3 in a genome-wide linkage analysis: the Framingham Heart Study. Heart Rhythm. 2005;2:277-284.
12. Newton-Cheh C, Guo CY, Larson MG, Musone SL, Surti A, Camargo AL, Drake JA, BenJ Amin EJ, Levy D, D'Agostino RB, Hirschhorn JN, O'donnell CJ. Common genetic variation in KCNH2 is associated with QT interval duration: the Framingham Heart Study. Circulation. 2007; 116:1128-1136.
13. Splawski I, Timothy KW, Tateyama M, Clancy CE, Malhotra A, Beggs AH, Cappuccio FP, Sagnella GA, Kass RS, Keating MT. Variant of SCN5A sodium channel implicated in risk of cardiac arrhythmia. Science. 2002;297:1333-1336.
14. Burke A, Creighton W, Mont E, Li L, Hogan S, Kutys R, Fowler D, Virmani R. Role of SCN5A Y1102 polymorphism in sudden cardiac death in blacks. Circulation. 2005;112:798-802.
15. Aarnoudse AJ, Newton-Cheh C, de Bakker PI, Straus SM, Kors JA, Hofman A, Uitterlinden AG, Witteman JC, Stricker BH. Common NOS1AP variants are associated with a prolonged QTc interval in the Rotterdam Study. Circulation. 2007;116:10-16.
16. Priori SG, Napolitano C, Schwartz PJ. Low penetrance in the long-QT syndrome: clinical impact. Circulation. 1999 Feb 2;99:529-533.
17. Roden DM. Druginduced prolongation of the QT interval. N Engl J Med. 2004;350:1013-1022.
18. Selzer A, Wray HW Quinidine syncope, paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias. Circulation. 1964; 30:17-26.
19. Dessertenne F. Ventricular tachycardia with 2 variable opposing foci [in French]. Arch Mal Coeur Vaiss. 1966;59:263-272.
20. Perry M, de Groot MJ, Helliwell R, Leishman D, Tristani-Firouzi M, Sanguinetti MC, Mitcheson J. Structural determinants of HERG channel block by clofilium and ibutilide. Mol Pharmacol. 2004;66:240-249.
21. Stansfeld PJ, Sutcliffe MJ, Mitcheson JS. Molecular mechanisms for drug interactions with hERG that cause long QT syndrome. Expert Opin Drug Metab Toxicol. 2006;2:81-94.
22. Kaźmierczak J, Peregud-Pogorzelska M, Rzeuski R. QT interval prolon-gation and torsades de pointes due to a coadministration of ciprofloxacin and azimilide in a patient with implantable cardioverter-defibrillator. Pacing Clin Electrophysiol. 2007;30:1043-1046.
23. Cordes JS, Sun Z, Lloyd DB, Bradley JA, Opsahl AC, Tengowski MW, Chen X, Zhou J. Pentamidine reduces hERG expression to prolong the QT interval. Br J Pharmacol. 2005;145:15-23.
24. Kuryshev YA, Ficker E, Wang L, Hawryluk P, Dennis AT, Wible BA, Brown AM, Kang J, Chen XL, Sawamura K, Reynolds W, Rampe D. Pentamidine-induced long QT syndrome and block of hERG trafficking. J Pharmacol Exp Ther. 2005;312:316-323.
25. Ra J, Amani S, Eckhardt LL, Valdivia CR, Klemens CA, Gillman BM, Anderson CL, Holzem KM, Delisle BP, Anson BD, Makielski JC, January CT Druginduced long QT syndrome: hERG K(+) channel block and disruption of protein trafficking by fluoxetine and norfluoxetine. Br J Pharmacol. 2006;149:481-489.
26. Singh S, Zoble RG, Yellen L, Brodsky MA, Feld GK, Berk M, Billing CB. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) study. Circulation. 2000;102:2385-2390.
27. Lehmann MH, Hardy S, Archibald D, quart B, MacNeil DJ. Sex dif-ference in risk of torsade de pointes with d,l-sotalol. Circulation. 1996; 94:2535-2541.
28. van Noord C, Straus SM, Sturkenboom MC, Hofman A, Aarnoudse AJ, Bagnardi V, Kors JA, Newton-Cheh C, Witteman JC, Stricker BH. Psychotropic drugs associated with corrected QT interval prolongation. J Clin Psychopharmacol. 2009;29:9-15.
29. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsy-chotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009;360:225-235.
30. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA. 1993;270:2590-2597.
31. Bednar MM, Harrigan EP, Ruskin JN. Torsades de pointes associated with nonantiarrhythmic drugs and observations on gender and QTc Am J Cardiol. 2002;89:1316-1319.
32. Lazzara R. Amiodarone and torsade de pointes. Ann Intern Med. 1989; 111:549-551.
33. Yang T, Snyders D, Roden DM. Drug block of I(kr): model systems and relevance to human arrhythmias. J Cardiovasc Pharmacol. 2001;38: 737-744.
34. Hondeghem LM. QT prolongation is an unreliable predictor of ventricular arrhythmia. Heart Rhythm. 2008;5:1210-1212.
35. van Opstal JM, Schoenmakers M, Verduyn SC, de Groot SH, Leunissen JD, van Der Hulst FF, Molenschot MM, Wellens HJ, Vos MA. Chronic amiod-arone evokes no torsade de pointes arrhythmias despite QT lengthening in an animal model of acquired long-QT syndrome. Circulation. 2001;104: 2722-2727.
36. Milberg P, Eckardt L, Bruns HJ, Biertz J, Ramtin S, Reinsch N, Fleischer D, Kirchhof P, Fabritz L, Breithardt G, Haverkamp W. Divergent proar-rhythmic potential of macrolide antibiotics despite similar QT prolon-gation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes. J Pharmacol Exp Ther. 2002;303:218-225.
37. Belardinelli L, Antzelevitch C, Vos MA. Assessing predictors of Druginduced torsade de pointes. Trends Pharmacol Sci. 2003;24:619-625.
38. Antzelevitch C, Shimizu W. Cellular mechanisms underlying the long QT syndrome. Curr Opin Cardiol. 2002;17:43-51. (Pubitemid 34073163)
39. Sims C, Reisenweber S, Viswanathan PC, Choi BR, Walker WH, Salama G. Sex, age, and regional differences in L-type calcium current are important determinants of arrhythmia phenotype in rabbit hearts with Druginduced long QT type 2. Circ Res. 2008;102:e86-e100.
40. Antzelevitch C, Shimizu W, Yan GX, Sicouri S, Weissenburger J, Nes-terenko VV, Burashnikov A, Di Diego J, Saffitz J, Thomas GP. The M cell: its contribution to the ECG and to normal and abnormal electrical function of the heart J Cardiovasc Electrophysiol. 1999;10:1124-1152.
41. Roden DM. Keep the QT interval: it is a reliable predictor of ventricular arrhythmias. Heart Rhythm. 2008;5:1213-1215.
42. Curtis LH, Østbye T, Sendersky V, Hutchison S, Allen LaPointe NM, Al-Khatib SM, Usdin Yasuda S, Dans PE, Wright A, Califf RM, Woosley RL, Schulman KA. Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients. Am J Med. 2003;114:135-141.
43. Liu P, Foster G, Labadie R, Somoza E, Sharma A. Pharmacokinetic interaction between voriconazole and methadone at steady-state in patients on methadone therapy. Antimicrob Agents Chemother. 2007;51: 110-118.
44. Pratt CM, Hertz RP, Ellis BE, Crowell SP, Louv W, Moye L. Risk of developing life-threatening ventricular arrhythmia associated with tefe-nadine in comparison with over-the-counter antihistamines, ibuprofen and clemastine. Am J Cardiol. 1994;73:346-352.
45. Hanrahan JP, Choo PW, Carlson W, Greineder D, Faich GA, Platt R. Terfenadine-associated ventricular arrhythmias and QTc interval prolon-gation: a retrospective cohort comparison with other antihistamines among members of a health maintenance organization. Ann Epidemiol. 1995;5:201-209.
46. Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantilena LR Jr. Torsades de pointes occurring in association with terfenadine use. JAMA. 1990;264:2788-2790.
47. Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr. Changes in the pharmacokinetics and electrocardiographic pharmacody-namics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther. 1992;52:231-238.
48. Jurima-Romet M, Crawford K, Cyr T, Inaba T. Terfenadine metabolism in human liver. Drug Metab Dispos. 1994;22:849-857.
49. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin J, Cantilena LR. Terfenadine-ketoconazole interaction. JAMA. 1993;269:1513-1518.
50. Mok NS, Tong CK, Yuen HC. Concomitant-acquired long QT and Brugada syndromes associated with indapamide-induced hypokalemia and hyponatremia. Pacing Clin Electrophysiol. 2008;31:772-775.
51. Kay GN, Plumb VJ, Arciniegas JG, Henthorn RW, Waldo AL. Torsade de pointes: the long-short initiating sequence and other clinical features: observations in 32 patients. J Am Coll Cardiol. 1983;2:806-817.
52. Bednar MM, Edmund P. Harrigan EP, Anziano RJ, Camm AJ, Ruskin JN. The QT interval. Prog Cardiovasc Dis. 2001;43:1-45.
53. Roden DM, Woosley RL, Primm RK. Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. Am Heart J. 1986;111:1088-1093.
54. Torp-Pedersen C, Møller M, Bloch-Thomsen PE, Køber L, Sandøe E, Egstrup K, Agner E, Carlsen J, Videbaek J, Marchant B, Camm AJ. Dofetilide in patients with congestive heart failure and left ventricular dysfunction: Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med. 1999;341:857-865.
55. Zeltser D, Justo D, Halkin A, Prokhorov V, Heller K, Viskin S. Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors. Medicine. 2003;82:282-290.
56. Ranger S, Nattel S. Determinants and mechanisms of flecainide-induced promotion of ventricular tachycardia in anesthetized dogs. Circulation. 1995;92:1300-1311.
57. Roden D. A critical reconsideration of the clinical effects and treatment recommendations for sodium channel blocking drug cardiotoxicity. Toxicol Rev. 2006;25:283-296.
58. Ruskin JN, McGovern B, Garan H, DiMarco JP, Kelly E. Antiarrhythmic drugs: a possible cause of out-of-hospital cardiac arrest. N Engl J Med. 1983;309:1302-1306.
59. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the CardiacArrhythmiaSuppressionTrial. NEngl JMed. 1991;324:781-788.
60. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction: the Cardiac Arrhythmia Suppression Trial II Investigators. N Engl J Med 1992;327:227-233.
61. Hallstrom AP, Anderson JL, Carlson M, Davies R, Greene HL, Kammerling JM, Romhilt DW, Duff HJ, Huther M. Time to arrhythmic, ischemic, and heart failure events: exploratory analyses to elucidate mechanisms of adverse drug effects in the Cardiac Arrhythmia Sup-pression Trial. Am Heart J. 1995;130:71-79.
62. Bezzina CR, Shimizu W, Yang P, Koopmann TT, Tanck MW, Miyamoto Y, Kamakura S, Roden DM, Wilde AA. Common sodium channel promoter haplotype in Asian subjects underlies variability in cardiac conduction. Circulation. 2006;113:338-344.
63. Qu Z, Weiss JN. Effects of Na(+) and K(+) channel blockade on vulnerability to and termination of fibrillation in simulated normal cardiac tissue. Am J Physiol Heart Circ Physiol. 2005;289:H1692-H1701.
64. Krishnan SC, Josephson ME. ST segment elevation induced by class IC antiarrhythmic agents: underlying electrophysiologic mechanisms and insights into Druginduced proarrhythmia. J Cardiovasc Electrophysiol. 1998;9:1167-1172.
65. Darbar D, Yang T, Churchwell K, Wilde AA, Roden DM. Unmasking of Brugada syndrome by lithium. Circulation. 2005;112:1527-1531.
66. Yap YG, Behr ER, Camm AJ. Druginduced Brugada syndrome. Europace. 2009;11:989-994.
67. Lin MT, Wu MH, Chang CC, Chiu SN, Thériault O, Huang H, Christé G, Ficker E, Chahine M. In utero onset of long QT syndrome with atrioven-tricular block and spontaneous or lidocaine-induced ventricular tachycardia: compound effects of hERG pore region mutation and SCN5A N-terminus variant. Heart Rhythm. 2008;5:1567-74.
68. Coull DC, Crooks J, Dingwall-Fordyce I, Scott AM, Wier RD. Amitrip-tyline and cardiac disease: risk of sudden death identified by monitoring system. Lancet. 1970;2:590-591.
69. Effects of encainide, flecainide, imipramine and moricizine on ventricular arrhythmias during the year after acute myocardial infarction: the Cardiac Arrhythmia Pilot Study (CAPS) Investigators. Am J Cardiol. 1988;61: 501-509.
70. Babaliaros VC, Hurst JW. Tricyclic antidepressants and the Brugada syndrome: an example of Brugada waves appearing after the adminis-tration of desipramine. Clin Cardiol. 2002;25:395-398.
71. Amitai Y, Frischer H. Excess fatality from desipramine in children and adolescents. J Am Acad Child Adolesc Psychiatry. 2006;45:54-60.
72. Lepor H, Lepor NE, Hill LA, Trohman RG. The QT interval and selection of alpha-blockers for benign prostatic hyperplasia. Rev Urol. 2008;10: 85-91.
73. Mareedu RK, Peterson JF, Miller RA, Boyle D, Matheny M, Waitman LR, Arrieta M, Roden DM, Denny JC QT-prolonging medication ten-dencies in a cohort of hospitalized patients with known long QT intervals. Circulation. 2008;188:S-1084. Abstract
74. McMullin ST, Reichley RM, Watson LA, Steib SA, Frisse ME, Bailey T. Impact of a Web-based clinical information system on cisapride drug interactions and patient safety. Arch Intern Med. 1999;159:2077-2082
75. ICH E14: The Clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-arrhythmic drugs. European Medical Agencies. 2005:CHMP/ICH/2/04.
76. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, Murphy SA, Budaj A, Varshavsky S, WolffAA, Skene A, McCabe CH, Braunwald E. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 ran-domized trial. JAMA. 2007;297:1775-1783.
77. Ray WA, Murray KT, Meredith S, Narasimhulu SS, Hall K, Stein CM. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med. 2004;351:1089-1096.
78. Odening KE, Hyder O, Chaves L, Schofield L, Brunner M, Kirk M, Zehender M, Peng X, Koren G. Pharmacogenomics of anesthetic drugs in transgenic LQT1 and LQT2 rabbits reveal genotype-specific differential effects on cardiac repolarization. Am J Physiol Heart Circ Physiol. 2008;295:H2264-H2272.
79. Kang J, Chen XL, Wang H, Ji J, Cheng H, Incardona J, Reynolds W, Viviani F, Tabart M, Rampe D. Discovery of a small molecule activator of the human ether-a-go-go-related gene (HERG) cardiac K+ channel. Mol Pharmacol. 2005;67:827-836.
80. Diness JG, Hansen RS, Nissen JD, Jespersen T, Grunnet M. Antiarrhythmic effect of IKr activation in a cellular model of LQT3. Heart Rhythm. 2009;6:100-106.
81. Milberg P, Pott C, Fink M, Frommeyer G, Matsuda T, Baba A, Osada N, Breithardt G, Noble D, Eckardt L. Inhibition of the Na+/Ca2+ exchanger suppresses torsades de pointes in an intact heart model of long QT syndrome-2 and long QT syndrome-3. Heart Rhythm. 2008;5: 1444-1452.
82. Alings M, Dekker L, Sadée A, Wilde A. Quinidine induced electrocar-diographic normalization in two patients with Brugada syndrome. Pacing Clin Electrophysiol. 2001;24:1420-1422.
83. Ohgo T, Okamura H, Noda T, Satomi K, Suyama K, Kurita T, Aihara N, Kamakura S, Ohe T, Shimizu W. Acute and chronic management in patients with Brugada syndrome associated with electrical storm of ven-tricular fibrillation. Heart Rhythm. 2007;4:695-700.
84. Gaita F, Giustetto C, Bianchi F, Schimpf R, Haissaguerre M, Calò L, Brugada R, Antzelevitch C, Borggrefe M, Wolpert C. Short QT syn-drome: pharmacological treatment. J Am Coll Cardiol. 2004;43: 1494-1499.
85. Tan BH, Valdivia CR, Song C, Makielski JC Partial expression defect for the SCN5A missense mutation G1406R depends upon splice variant background Q1077 and rescue by mexiletine. Am J Physiol Heart Circ Physiol. 2006;291:H1822-H1828.
86. Moss AJ, Windle JR, Hall WJ, Zareba W, Robinson JL, McNitt S, Severski P, Rosero S, Daubert JP, Qi M, Cieciorka M, Manalan AS. Safety and efficacy of flecainide in subjects with Long QT-3 syndrome (DeltaKPQ mutation): a randomized, double-blind, placebo-controlled clinical trial. Ann Noninvasive Electrocardiol. 2005;10:59-66.
87. Valdivia CR, Ackerman MJ, Tester DJ, Wada T, McCormack J, Ye B, Makielski JC A novel SCN5A arrhythmia mutation, M1766L, with expression defect rescued by mexiletine. Cardiovasc Res. 2002;55: 279-289.